Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.52 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | IDO1 | P14902 | 2/20 | 0.47 |
| ▸ | HTR6 | P50406 | 2/20 | 0.46 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | MMP13 | P45452 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4916688 | 1.00 | MEN1 (0.52) | MEN1KMT2ATDP1CHRM2TAAR1 | |
| SCHEMBL5034657 | 1.00 | MEN1 (0.52) | MEN1KMT2ATDP1CHRM2TAAR1 | |
| SCHEMBL4911510 | 0.98 | MEN1 (0.54) | MEN1KMT2ATDP1CHRM2TAAR1 | |
| SCHEMBL4918654 | 0.91 | TAAR1 (0.55) | MEN1KMT2ATDP1CHRM2TAAR1 | |
| SCHEMBL4919186 | 0.91 | TAAR1 (0.55) | MEN1KMT2ATDP1CHRM2TAAR1 | |
| SCHEMBL4908617 | 0.91 | TAAR1 (0.55) | MEN1KMT2ATDP1CHRM2TAAR1 | |
| SCHEMBL7813797 | 0.90 | MEN1 (0.47) | MEN1KMT2ATDP1CHRM2TAAR1 | |
| SCHEMBL9737112 | 0.89 | TAAR1 (0.54) | TAAR1CYP2D6ALDH1A1IDO1DNM1 | |
| SCHEMBL31177924 | 0.88 | TAAR1 (0.55) | MEN1KMT2ACHRM2TAAR1CYP2D6 | |
| SCHEMBL10077141 | 0.88 | CYP2D6 (0.50) | MEN1KMT2ATDP1CHRM2TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3390483-B1 | ENCAPSULATION | PROCTER & GAMBLE (US) | 2022-05-18 | — | — | EP | disclosed |
| EP-3368207-B1 | ENCAPSULATION | ENCAPSYS LLC (US) | 2021-12-01 | — | — | EP | disclosed |
| US-10864167-B2 | Encapsulation | THE PROCTER & GAMBLE COMPANY (US) | 2020-12-15 | — | — | US | disclosed |
| EP-3390483-A1 | ENCAPSULATION | The Procter and Gamble Company (US) | 2018-10-24 | — | — | EP | disclosed |
| EP-3368207-A1 | ENCAPSULATION | ENCAPSYS, LLC (US) | 2018-09-05 | — | — | EP | disclosed |
| US-20180235893-A1 | ENCAPSULATION | THE PROCTER & GAMBLE COMPANY | 2018-08-23 | — | — | US | disclosed |
| US-9937477-B2 | Encapsulation | WATERTITE PRODUCTS, INC. | 2018-04-10 | — | — | US | disclosed |
| EP-1914254-B1 | Crosslinkers for improving stability of polyurethane foams | EVONIK DEGUSSA GMBH (DE) | 2017-08-23 | — | — | EP | disclosed |
| WO-2017074997-A1 | ENCAPSULATION | ENCAPSYS, LLC (US) | 2017-05-04 | — | — | WO | disclosed |
| WO-2017074995-A1 | ENCAPSULATION | ENCAPSYS, LLC (US) | 2017-05-04 | — | — | WO | disclosed |
| US-20170113200-A1 | Encapsulation | Encapsys,LLC (US) | 2017-04-27 | — | — | US | disclosed |
| US-8552078-B2 | Non-fugitive tertiary amine catalyst and alkylated polyamine crosslinking additives; aging resistance | AIR PRODUCTS AND CHEMICALS, INC. (US) | 2013-10-08 | — | — | US | disclosed |
| EP-1914254-A1 | Crosslinkers for improving stability of polyurethane foams | Air Products and Chemicals, Inc. (US) | 2008-04-23 | — | — | EP | disclosed |
| US-20080090922-A1 | Crosslinkers for improving stability of polyurethane foams | EVONIK OPERATIONS GMBH (DE) | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180235893-A1 | ENCAPSULATION | ACR, ACMSD, SAMM50 | MEN1 2236/4885KMT2A 1601/4885TDP1 810/4885 |
| US-10864167-B2 | Encapsulation | ACR, MPHOSPH6, ACMSD | MEN1 1901/4885KMT2A 1564/4885TDP1 653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.